A Single Dose Study to Investigate the Pharmacokinetics of Odanacatib (MK-0822) in Subjects With Renal Insufficiency.
Phase of Trial: Phase I
Latest Information Update: 23 Dec 2014
At a glance
- Drugs Odanacatib (Primary)
- Indications Male osteoporosis; Postmenopausal osteoporosis
- Focus Pharmacokinetics
- Sponsors Merck & Co
- 08 Oct 2013 Results presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
- 11 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.